BCPC - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Balchem Corporation's Second Quarter Financial Results Conference Call. [Operator Instructions]. A question and answer session will follow the formal presentation. [Operator Instructions].

As a reminder, this conference is being recorded. to conference like host, to now Mr. would turn over the your I Bengtsson. Martin Please proceed.

Martin Bengtsson

gentleman, joining this CEO, Corporation Ladies this you Financial our My thank and for Chairman, Bengtsson, Martin me discuss ending XX, Chief results is name quarter Harris, is morning and our the of with the and Balchem hosting President. for Officer, June XXXX. call to call conference Ted

our of auditors the counsel, Following the advice SEC. and

This to belief statement. does no prove our expectations, like differ forward-looking that which assurance risks to events identified reflected expectations read likely At contain, including contain, that We statements this time, risks will give forward-looking or and correct, I in Balchem's would factors reflect our will various factors Form Balchem's concerning XX-K. involve the results materially can release and forward-looking statements uncertainties. in expectation and from the or cause could future

I this qualified are Chairman, President. statements Forward-looking Ted Harris, call CEO, statement. in turn our and entirety by over the to cautionary will their now

Ted Harris

of in welcome quarter morning, net GAAP of and we resulted and million, gentleman, reported conference million $XX.X sales per our $X.XX share Martin. Good on which This Thanks, quarterly call. income ladies consolidated net or basis. to $XXX.X morning, first a

detailed million or per or an $XX.X These release $XX.X versus as first year with this items operating morning net of facilitate year. of $X.XX net per increase or noncash of our earnings $XX.X press $X.XX share and $X.X earnings in this quarter morning million other our the earlier compared to million non-GAAP performance of share exclude prior evaluation Our per million comparative earnings X.X% or quarter reported represent share. non-GAAP million of $X.X $X.XX prior amortization release tax-adjusted in of the

$XX.X million of first quarterly with quarterly flow We cash of operations also from flows million. for free delivered $XX.X the cash XXXX quarter

decline segments X.X% were Human in year Products, Health of euro, achieved to and Products quarterly and year. segments, segment Our to Nutrition where a fracking our Health in quarter. point the $XXX.X impact remain was our oil We million related growth compared quarterly more impact lower prior in driving and by XX sales negative to all-time our million sales record offset of due growth. sales volumes comparable a basis X than prior Industrial low were exchange sales foreign our than net negative which the and in Nutrition sales with year-over-year our to record The weaker the quarter to $X.X of second Animal our gas Specialty X

$XX.X million dollars $XX.X Our consolidated of for the X.X% million prior or in million year. gross QX compared the up $X.X margin period same with were

sales business result basis XX.X% was lower to primarily margin by European of percent the and Our quarter, from monogastric in grade XXXX. choline activity. in QX of up points of due feed competitive was volumes mix, offset margins XX as consolidated gross XX.X% the in increased The a increase partially

$XX.X were the expense. million compared increased and acquisition increase in due Chemogas prior operating The expenses the as debt year. incremental the XXXX to principally related for $XX.X operating to quarter expenses bad to Consolidated second million was

XX.X% intangible Excluding with expense expenses of assets or $XX.X noncash were of associated million operating sales. $X.X operating amortization of million,

existing tightly will our controlling leveraging Looking expenses infrastructure. forward, we on SG&A our operating continue and to focus

for $XX.X Adjusted million as operations release prior was decreased or our an detailed X.X% $XX.X adjusted down or million million GAAP in effective earnings the The million the tax XXXX million XXXX decrease were EBITDA attributable company's discrete for expense earnings $XX.X morning, million in posted second rate XXXX basis, million our the earnings was year. debt compared to $XX $X.X XXXX. $XXX.X million $X.X and and compared $X.X quarter were the rates quarter second from from XX.X% million below The the tax net was year. were prior in million. in respectively. to items. $XX.X Second X.X% this $X.X primarily quarter the effective XX.X%, second operations quarter Interest was On of to of and which of

net million $XX.X prior at income Consolidated $X.X the quarter. closed up the million, quarter from year

into $X.X result the quarterly $X.XX with current translated per net income net our of quarterly On for last adjusted detailed year's in basis, an year, and of earnings This flat share $X.XX. $XX.X diluted as per comparable our in release, or quarter. $X.XX earnings or quarter prior with share, the X.X% per $XX.X up million or million share year $X.XX diluted million adjusted second compared were net earnings diluted

capital million, quarterly reflects the free second on million expenditures year $XX.X quarter the of payments million quarter debt an which cash prior generated $XX.X the and of of loan acquired in to compared million $X.X closed revolving flow quarter, out cash increase the sheet, $XX.X of of and XX.X% with we XXXX. balance and of We

Belgium. is this and Grimbergen, held the production with a facilties our our closed Asia, we you fit by initiatives. privately existing of strong activities call Specialty within Last to the oxide company we definitive Chemogas, a gases agreement announced to signing to May to strategic specialty its a segment. Martin quarter, acquisition. would headquartered Products ethylene on few cover repackaging update the key NV, passing the results XX On formally Before like this quarter, with acquire Chemogas business I Europe in detailed of back in of growth an segment, and

Balchem our products for gases which business We are services we and worldwide, will acquisition to Performance this focused on other global call Gases. leveraging needs ethylene oxide a create customers' specialty that

pulling of continuation of integration ensuring together of tasked efficiently cross-functional the performance level business has years. the team A high recent of the while Chemogas the business with been the

coming opportunities creates synergies manufacturing Balchem. We're work we material raw acquisition realize integrate the months. costs, revenues, to about into SG&A, working on over potential see the we are synergies to Chemogas for and As hard and excited Belcham, and those this

of Health Study see the to calls, we on to previous if as University Nutrition first study the discussed year have cognitive our invested pregnancy and segment, Within seen a during in benefits in Balchem Choline follow-on X the Cornell Cornell who the Human life have Supplementation at as later and old, testing same neurologic children years now to affectionately, cognitive childhood. are into conducted extensive Chol-Kids. persist study The who initial the during referred on the now researchers are

data maternal is consistent report meetings with attention, cognitive choline indeed to pleased scientific preliminary at presented maternal are memory, does the an been of This of improve animal the and large effect lasting body choline at X on offspring. international executive We highly that show results have the in and increasing age. that function several demonstrating function years of

end peer of results journals look The year. have their by forward we been review submitted hopefully publication the and to to the

We results this of and choline and for are health. use of mother these the about extremely that will findings study and awareness believe child further the excited advance

CureMark trial their to X Montreal. presented were the work recently a and of III Society known also Blum regards completed autism, Meeting Autism for stage With their International trial. unique we the results clinical May in at treatment Research on These develop were to the as of pleased with results

placebo-controlled Deborah preschoolers clinical disorder CM-AT The behaviors reduction Child associated X at old with years Dr. and the Pearson, week is participated criteria maladapted Psychiatric with X Houston. presented Professor presentation Therapy randomized, preschool by autistic double-blind, Pancreatic this titled autism. meeting of of Adolescent in with Texas It for was the in XX University Replacement XXX ages through trial. established children in

in improved inappropriate hyperactivity, CM-AT. The statistically preschoolers placebo objective of to reductions Blum received relative the the irritability, speech with with such could and XX autism if participants study significant showed and After specifically hyperactivity behaviors behaviors be group. associated short autism, ascertain of relatively in in to was maladapted timeframe who as with CM-AT the trial irritability in weeks, the the

XXXX, press autism. treatment Fallon, the population. for trial May patient the X CM-AT CEO in given as X data Joan dated are of limited noncore children options core with that youngest including suggests Dr. These findings summarizes this has the promising and CureMark, an follows, on through our her Blum ages communication, release in effect symptoms, findings X, of

CureMark trials closely a supply Application filing patients of their work that to Biologics CM-AT. prepare continues the with to to have Balchem ensure enrolled ready with open-label ongoing FDA and for License in

in system our have we a a staged have system by to previous important the a one-third with our ERP one, quarters, into initiative and year. consolidate then implementation sites. across and of systems on Microsoft on the new lastly, company efficiency discussed and next April and manufacturing is to year critical started and ERP have we schedule for project embarked of our almost Dynamics planning, growth have consolidation continued company. We network financial new are million so revenue on now XXX% $XX users of of on businesses After an operational X our last this we with the And implementation time as in This XXX. believe first of or year,

I'm to each now to through call results back our turn going Martin for to of the detailed go the over segments.

Martin Bengtsson

Ted. Thanks,

Human record prior and driven million or of For $XX.X increase $X.X achieved quarter segment a increase quarter, second Cereal Human nutrients our and partially our offset solutions particularly Systems higher infant ingredient a decrease for by formula and sales. choline the the an primarily our of from Pharma Nutrition business, sales in million, sales was markets, in and by Nutrition supplement Health year. X% The sales business the

increase second quarter $X.X earnings also favorable operations segment and or of to $XX.X year XX.X% Health and an million mix, prior to expenses. Nutrition primarily record from Human operating compared million, lower delivered sales, higher due of

or were expense an million quarter. quarter year $X.X million, in we to earnings Excluding a increase compared disruptions. to supply with Animal the saw record to in the acquired compared of for prior million due year, the $XX.X segment XX% intangible the the assets an effect despite Chinese for and were $X.X of this prior adjusted increase million, million, segment our and Sales choline Health of second noncash amortization $XX.X X.X% of Nutrition million $X.X of from or for the one-time operations prior $XX.X associated benefits

markets ruminant the Sales monogastric chelated product year of second the XX% X% higher of exchange million million increased a Sales our targeted market to with impact is foreign minerals feed prior of $X.X impact feed choline $X.X or impact the sales. in being increased negative in X.X% a from or species negative the notable grade $X.X by growth. most by for to ANH compared global driving with by prior increased quarter, driven segment The volumes. partially offset decline in year-over-year million lines product a into animal year, sales

business. activity of monogastric by and Animal increased operating of in sales, were primarily European operations to competitive the due and increased margins quarter Nutrition from down of and due and driven earnings research prior impacting year result million volumes ruminant a $X business marketing, to Health in negatively and lower expenses quarterly development the also from $X in and margins, as our pricing investments million

Specialty lower for business in and weather Products the sales million of in higher segment driven legacy of achieved plant by increase record medical increase million quarter sterilization $XX.X of Specialty higher by of oxide The volumes, million second device the quarter, $X.X million. the Chemogas million both volumes The partially earnings nutrition year Products ethylene operations by to conditions. the prior were was from primarily market $X.X sales unfavorable of the quarterly for prior an offset quarter. driven $XX.X $X.X versus compared with due as contribution X.X% year all-time

were $X.X with $XX the year. of to earnings effect partially primarily intangible million, Chemogas the increase primarily Excluding higher adjusted driven expense second assets from by segment quarter of sales, by the higher by of associated prior The acquisition. expenses was $X.X driven in for operations offset million million compared amortization this operating noncash

the derivatives the from $X.X primarily Products million In reduced $X.X or of segment, used XX% in shale decreased due million fracking prior and Industrial choline sales the to sales choline of applications. year

and around believe remain cyclical solutions we've hard XXXX, historically and downs. the to that seen the cautious transportation accurately we fracking the will but forecast it's start yet. this that second oil for gas logistical activity and completed any of about We not half to are ups improve in Basin, As market of Permian indication

Industrial $X.X Products million, segment year sales with compared million Our volumes. operations due to for earnings were prior lower from of quarter the a decrease the $X.X the

some for I'm going Ted remarks. to call to now turn the over back closing

Ted Harris

net the as solid segments while Thanks, we and certain quarter, facing year-over-year comparative four flows headwinds consolidated previously revenue oil business, operations well cash noted In our gas across monogastric and as three within our delivered Martin. second with from of earnings growth business. our

within strong have positioned are the positions the we to serve, believe come. we markets We healthy generate years to growth well and over we

clearly companies will our of to more Chemogas about are service ability our the the creates critical oxide of We a which to combination medical and of the sterilization NV. the industry, acquisition significantly global enhance excited The device supply global very two customers on our in basis. leader ethylene support

the key our with our that markets. are and made XXXX, opportunities in in on well We initiatives we capitalize are believe to we positioned growth pleased progress strategic growth on QX the

We on exercising focusing will our our continue to core by value-creating management, strengthen and disciplined company cost acquisition opportunities. seeking strategies,

the up call like who the call I back questions. to will hand to Martin, Martin? open would now for over

Martin Bengtsson

now concludes This of At we call Ted. will point, Thanks, formal up for the the this the open portion conference. questions. conference

Operator

will be answer a session. conducting [Operator and Instructions] At this question time, we

Our of Hundley comes first question Seaport Brett from Securities. Global

Brett Hundley

supplements and business the your you segment human to choline sales Martin, start HNH there. driven prepared higher pharma in part nutrition side. the wanted on in choline mentioned noting remarks I had in were how your by

of through a call understanding sense of some for you going these today, findings wanted to published, having there? your the know talking earlier how you're conversations need and guys but really be just between both and as I be to I you us still light follow-on your choline take you last be give how you conversations about set can just the developing get an in see your referenced they would choline a and That you pipeline were us just And might that to that of helpful. customer findings.

Ted Harris

quarter Sales The bit at year-over-year take after We choline follow-on really customers time, are we're in that today about, by pleased talked were higher of long the the start I'll approximately the think, well X-year-olds. nutrients were a that have increased as sales having than the QX. at up a XX% with conversations a in in that, Brett. in part with the to at, to original a a soft they relative stab Cornell I QX. fueled really year as been level least we've the in study study the

lot encouraging of of a maternal benefits of years at is to This relative are sustainability the getting results cognitive X really attention least till choline. and the

at vitamin opportunity this is we've and we attention. think, higher front So talking, customers. about really center with getting us as as far level best is We're look most lot our before, for as talked And at and I scientifically here pipeline, now. our prenatal a area of significant as the a and the

regimen. rarely vitamin ago years Two was prenatal choline included in

new the like I label think product that's and dramatically come Made, choline. Pharmavite vitamins even on changing. We've seen prenatal big with including choline, new promoting Nature name with out brands, the the fact that contains

perspective, the it's fatty So exciting adult associated and multivitamins, issues our and even is And liver now, opportunities, really, with positive. opening up around other discussions from and pretty here that's it cognition, diabetes. but

us docket, higher-level of choline So can vitamins creating, where a the leading and play these are kind all role is things prenatal of think, first on growth. a that's kind I path but down of all it's this discussion

Brett Hundley

of reminds this you seen there. I situation kind out don't me this, one that agree I've if of Ted, with know And another

been time number skin it and benefits. this a product, number of of had benefits, your a of long ingredient a peers producing other had One for squalene,

thought with set waiting channel just remain And for traditional its customers. company yourself, into branded comes the more its something And you developed generally ingredient branded products a it kind BXB more out further to this products to created kind a using the develop developing itself for the squalene or of created CPG you want itself any to product. and seller? is where it choline, buzz have sales that and guys about of consumer When went of instead really then CPG the products customer and

Ted Harris

are cobranding. Pharmavite us, opportunity leaders BXB for about thought that, remains sales really it with about have working while thinking we and, Brett, like that and focused on an We option

their We or doing are getting with companies. as customers those VitaCholine and Balchem comarketing some our of our on brand include to choline kind even for of labels,

well their as is focus and we're So that attention at primary getting attention, really our this as and point. like feel do today we our focus the that's industry's really

Brett Hundley

your me business. then question queue. animal back one from and a And I'll ask to Great. in on you more wanted jump I

on as about XXXX Do over here? move side talk of kind pricing animal relative expect you your into can we energy and been complex pricing just Animal around on if product as for late. bouncing stability side. Products So of all has formulas place the The the you the

Ted Harris

do. did pricing so in filling in we our Yes, We've have Clearly, where down. margins seen they seeing late early obviously XXXX, unusual as supply void. and in that in China moved up, XXXX, out situation and the of an prices business, you're up that and is come our our back now volumes dried

business really a but relatively that major European stable. is somewhat are our play And role, feedstocks our Chinese elsewhere the uniquely to where

Our see don't kind of into gone carrying that normal pricing significant a is pleased Nutrition that grow for situation XXXX. really expect relatively stable were to year-over-year European performance despite And encouraging that and of We sort we we of on to the comp our changes. has business we able new us. we see in fact any issue The monogastric actually the that and were QX. with Animal revenue was

ruminant quarter. Our had business a good

that supply. as and could some they little not should around in in and increasing contents benefiting choline increases diet. require are So We've African materially and situation the demand inclusion we swine anything overall it corn The and are relative in the U.S. and think study starting it. signs has. were pricing of picture, of don't and balancing we fever impacted recently in found see a just hasn't our are should we that actually pleased Europe continue right to choline past start production, the demand done And to choline significantly soybean now as impacting specifically although see really we integrators

specifically business around to reasonably pricing. question all-in-all, we feel good about your So and the

Brett Hundley

you is you that Did I I'm as competition? it QX correctly the European hear said normalizing sorry. to from relates situation Chinese

Ted Harris

yes. Yes,

Operator

from Our at Tim question next Ramey comes Research Group. Pivotal

Tim Ramey

where know for the the going to helpful but I'm that left specific Is I XQ would flatlining wondering animal I give continue what you stabilizing off side, guess or in recover margins? segment can don't of levels the on we're if sort we're or guidance, mean that I'm Brett to from I by know margins it stabilizing, be could. can margins sort you if of at recovering. those if recover.

Ted Harris

came now the QX. the share back to from are They slowly recover opportunity talking have we think that and capture, They I QX should they're Chinese I'm dynamics. The competitive at first When we back. about in largely clearly in I back. So really stabilizing. margins think to stabilizing, about and QX that have I of some talk recaptured going are margin see benefit some that an

QX do I going ultimately is we'll see think forward. what lower So than a little

Tim Ramey

And would Sounds a on what have choline good. time and of study longitudinal so your be ago, infants, bit long or about what prenatal supplementation choline? it changed. consistent dose can the I a views you the was explain that was be mean, should current view may with more little on

Ted Harris

So women. pregnant the to known women daily was as for trimester in a of was what of is really fed kind today third the intake actually choline. was double the recommended the dose that the It dose high

choline that results. favorable it dose So was high of generated positive a the

but be a included that milligram part the have daily Study of included And about That's at, recommended should of woman what X% choline XX% the multivitamin, so task only level. maybe about in of it's ahead. suggest often a and XX say, a When taking. opportunity that's pregnant let's would intake Cornell we is the

opportunity. see we as so an And that

of even for to but choline recommended take the do that, as be XX% inclusion to the single daily daily get regimen we do that dose. we single higher how vitamins we'll or get actually prenatal standalone tablet tablets of the two of to a increase significantly Okay, part the intake, how

Tim Ramey

the closer this math like on is just doing what what something you gram it Just trial. a said, sounds to

Ted Harris

yes. Yes,

Tim Ramey

Interesting. nice. That would be

much. it I'll back. hand Okay, good. so Thanks

Operator

from Wainwright. Our H.C. of Selvaraju Raghuram next comes question

Edward Marks

you Good morning, I appreciate Marks the for taking this questions. is on Ram. Edward

Just a little bit. out a few for spreading me,

facility wondering might this impact wondering possibilities. products hopefully oxide Sterigenics the acquisition ethylene and in on the how Just this the then just after might arena, Chemogas with prevent in just from considerably how your expand ban Illinois, reopening the that oxide especially its ethylene might presence

Ted Harris

has and So on thanks Obviously, spending of there we're been so. progress last we the have lot important question. talked in X a time a is an months issue this made this, but of lot the for or and certainly

have the So after with an resume site facility was Willowbrook, think Sterigenics operations. to to which the will the shut in mid-February, down I finally of in they Illinois, Illinois come State was, enable it agreement

positive a we step. So that as view very

so new it They Illinois, not of oxide. a fact lower on with equipment is and they State So standards. can believes lowered for in have exposure additional and some ethylene limits meet ban the Sterigenics that emissions the those forth

they're be Obviously, So they are and certainly reopen, before by the planning on our plan Illinois forward reopen. their EPA to from needs reopening. moving but approved to understanding they plan

of System, perspective, XXXX. months brought this seriously that Council IRIS. positively in Integrated called seeking the few or was a Information about correction a also filed from risk IRIS, by EPA to very I the done Certainly, American petition the U.S. assessment facility it's last assessment our with shutdown the December think has Chemistry And that Risk in the by as flawed was published pretty the risk EPA of

value has so not even supported maybe And ACC, the very Quality, also presented was the Commission And more has Texas adequately evidence their determined ACC that scientific on the correction. by the positively, data. support Texas the scientific IRIS really to Environmental EPA, than and

their assessment So EPA the therefore, to significantly IRIS. different has, the is own Texas which published value,

even toward decide they the multiple will use the they And think levels we now that industry something and tightening I set and live EPA and work limits. exposure the controls what market evaluate all has they exposure ultimately limits, to would emission assessments for lead assessments and multiple controls now that has EPA can so, be And Texas and can ACC to within. decide the we what but decide emissions believe assessments that to this We as do. think what suggest to will ultimately because do believe the

So to from any we'll Belcham ensure good make used closely new prepared is continue by regulatory and as to situation come appropriate the of this authorities that course, to it planning to with do all that evolves data ACC also, being this, reopening is with work that scientific exposure the regulations Sterigenics that that positive stakeholders ensure limit decisions, science of but to meet certainly, out to exposure we will is and we on assessment have and as limits. provide, all set see the come challenge and new assessments the EPA IRIS new think good that Texas use as they may

Edward Marks

going you appreciate that I all Perfect. detail. into

and Industrial to in East into the half the impacted a production bit. of over and was So and the as choline I on of second demand into and if prolonged moving oil any shale the price choline might looking affect just have the how that you're XXXX. for conflicts the Middle timelines some prospects past maybe the any might mentioned for Products, wondering geopolitical deposit Basin you volatility maybe in and quarter Permian little

Ted Harris

prices pipelines Obviously, for if where Basin Oil price, oil disappointment and the Permian the coming a there really the part think geopolitical does completed. the a prices of and that to we this associated of a rapidly volumes least benefit at matter, performance. there overall oil gas. activity, least in We last don't anticipation with of is primary Right course, now, in choline. really slowing issue see being significant related us fracking completed once One, played in drivers in quarter. up at that X role, was oil The significant down are those quarter. the the was significant ramped and costs transportation would clearly poor

lower that. choline And of are within production. pick-up those on less is of completed, the I And a free discipline capital cash focus from perspective there's an in us expect, so new levels a of their activity use There's move that they flow sense fluids. staying a being both, I'll activity secondly and think, included there be things on do toward but, and impacting reduced in skimp role. still way in avenue just more kind clearly once every as but cost will efficient we anticipation But include. operators' skimp make fluid to and looking costs one cutting I they fracking to, do fracking playing really is to at if and to that's make that are mean even components word

see and so And now quarter long-term few in the less but over the really the driver. as biggest oil drivers so those we two quarters, that's price are last right a clearly

Edward Marks

methionine Those it. And I'm finally XM, remarks is points. that good in then in rumen-protected, the really of but this missed terms may wondering AminoShure Got currently just have going. were prepared the I quick, product, just the how rollout

Ted Harris

picking On methionine, balancing do with sense protein morning, going make prices these the is well. This milk amino of this note, really of just acids, the product. really We kind specifically and next that's So are generation positive prices prices methionine protein up. a protein got new levels. milk and milk

new milk the formulations. the we that positive. incorporating their product feed encouraged have we're in leading Right in the a launching favorable trialing around clients' we're environment product, more now, protein, so for product that's nutritionists So a dairy country

we've think and product of I interest in the good levels new technology. the received

by encouraged initial we're response. the So

supply have the product and We some into to chain kind that of benefits of seen dairy our all see pushed really waiting in that we've farmers the the realize studies.

the encouraged more by to but receptivity come of the least to we're sort on at initial that, technology. So

Edward Marks

glad note. the high to Well, thanks end so a for taking That's questions. all on me, from Excellent.

Operator

Goldstein from Partners. Monica of Instructions] Lawrence comes Our next [Operator Santa question

Lawrence Goldstein

a happened anyone you haven't August, that send June, secondly word. a to it and heard of a be and copy CM-AT, in then? wants July, since or A me here May able Would request. we question Montreal, who what's study are in

can't brief what of do few it for out the And interpretation I wonder but and that is really I study a why a of release they paragraphs her press her it with is say if why all speak you'd said put you is know nothing. comment

press it all which summarized was in and of You study. release. had just about study and I her a any presume, she detailed lengthy, she is couple said sentences, nothing you The had

Ted Harris

we access we Larry. study a was and Thanks all in that it to it don't is have over Sure, access what release. you we that. presented press Montreal, she the but any for put in really to have is, that is what have The questions. And don't to really accurately control stated decides

attend presentation end again release. detail what in someone certainly which the included press there of is more have what's our did primary there, it was - the at conclusion, the and but in her in think Montreal I we the supported day included and We

And that that and and ultimate study. And is the was the areas. finding that statistically improve core CM-AT result did really in noncore those the ultimate fact of

with we're pleased So that.

positive a very I don't milestone I access really again that's get into, to… have think results. can't And significant and

Lawrence Goldstein

Can What attended number percentage? I the tell word. who What the person mean, is a the what anything? word statistically statistically was? you

Ted Harris

Right.

Lawrence Goldstein

Y or percent X

Ted Harris

Yes, absolutely.

And to in was there submitted was is that and for abstract. there the And presented believe an that that general Montreal. I public I access a think to way so abstract get also

So we'll look abstract get you that. access into do and detailed know and to see how possibly how people let others that can into more

Lawrence Goldstein

you. Thank

Operator

from Sidoti. comes Mitra question next of Ramgopal Our

Mitra Ramgopal

or cost First, terms quarter. look And wondering the half? for a couple that early it second synergies much how should of questions more just was revenue contributed in and as I on XXXX is expectation that Chemogas. as the we in

Martin Bengtsson

line it in the second a synergies, quarter. the one in we in we of had an our in model it, here closed quite We from line were modeled more et This pleased consistency of with revenue is the way came May, so for them. their cetera, month. of them expectations so And and the sort with and and they is of end contributed integration And month The we XXXX. from delivery the just essentially Chemogas with had Martin. our earnings at first on

disclosed earlier think synergies we in would million $X.X run-rate expect we range. that I the

We that. path see a clear to

Here in we have integration also the beginning associated obviously it. with costs some

So you're XXXX. going benefits these start not really until seeing to

Mitra Ramgopal

more. any terms Okay. terms even for costs this was there? get No,that's seeing margins great. commodity in FX are is the to know of I trying I quarter you of raw headwinds headwind in or you up a materials wondering

Martin Bengtsson

in favorability actually $X for raws. Yes, Raw about quarter second the somewhat favorable, the from Mitra. were materials in of us million quarter

$X you and the remember also And If the benefit in strong second QX this which Health you exclusively in our Human Nutrition not in in our why factor and see it Human first showing quarter margin a the had is segment. Nutrition us and driving release, segment, almost of in quarter. growth we for was up is Health million about

was the slightly For other a unfavorable driver. businesses, X not three actually It materials raw segments. the was in other key

Mitra Ramgopal

$XX million on Ted being That's the wanted How to sense on I had far that? I get And that. allocated we track. terms ERP a to of know along are initiative Okay. that's said in also perfect. the is just you

Martin Bengtsson

well we're Yes, progressing on D-XXX.

project we we here future under date. look sit confident or least in that come this, not as to And completing into expense very As here budget. we will would exceed this we that we've million to $XX million communicated before, close we incurred view $XX approximately one a and the the are of at and between million as budget for CapEx project. We've as out $X

this So we is progressing. how with feel quite comfortable

Mitra Ramgopal

quarter now, the know Okay use rate, obviously items. to also last this over discrete still number going it Is And, on couple moved some Martin, has forward? quarters XX% and the a tax fair thanks. I

Martin Bengtsson

because a second of XXXX, discrete would had that full for a have year more we'll a think discrete here in in quarter outlook, item will XX% bit impact we I the revise item this and little a to QX. XX% I the the year,

future would any XXXX. So then based to forward years, as I of as Then, discrete look aware year a in return don't on instead full that again of, basis XX% use XX%. we predict I we're going XX% I model so on would items you

Mitra Ramgopal

Okay, companion one the at were looking if any you wondering back animal you is market. know there. segment, was the of I thanks. getting just to things the coming I great. Nutrition That's Animal traction Ted, were

Ted Harris

know, talked products always You and I've are. we've food launched pet this we the of PetShure been business. mean about, line I we've that in

new products is line that So off of grew by kind we about to in this this QX. build that have, really of small of trying but positive existing position actually XX%

have not of of broiler market growing So that part since asked about, unique penetrating to are certainly some Its did products market we attractive an talk like have the traction. base, and quarter. It's faster a so it's a the well. than but part market. we so we the monogastric small really It's the nice you feel getting material we differentiated are

pleased the quarter. were with So we

to to up things the a going it's think of indication forward, positive bit receptivity was QX in little be about but a of going again, and an trends the and story I feel, down to we great the market. products come. the And

Mitra Ramgopal

say you finally I Chemogas recent transaction but on term about a pipeline, just again, there's know this acquisition this much kind is you can thanks. Okay, precludes anything if until nice only wondering was I obviously this integrated. fit and then near of so the just get And

Ted Harris

It preclude really anything. doesn't

Our balance sheet is strong.

X.X, strong record a our debt debt do paying X.X. making after acquisition. net generation kind track an We'll cash down really had is sub to around of that. continue with EBITDA of We've Our good to

team reasonably are really the preclude opportunities as business job And there. corporate other or business So to our fully is radar it identifying focus pipeline being on opportunities us. by We've, a like that that now unit There Chemogas the the little things. of that of is doesn't like almost out healthy. there. good done This past screen. are part unit, development of is managed ones And and free off bit out the continue we in see think, I IFP a to

Operator

Tony question final Our from comes Aegis Polak Capital. of

Tony Polak

idea you BLA will Do actually any when filed? have the be

Ted Harris

been think what wrong in things is start do NDA that positive a delay a question in tougher about filing. results somewhat does the should we it past. we've the because this be and I show were the versus to project the thought partly of answer that one if to have that's we XXXX Tony, some I would BLA XXXX NDA an think saying with

think I material start XXXX/XXXX of us type benefits to realizing for timeframe it's more now this. a from

there's again, to informed bit part. delayed in based So on the speculation from our of but industry the forth. well. as things could so the little well, on a certainly there it exclusivity It's somewhat, and that benefits and are expectations, no like years as XX that's with speculation But, BLA question the vary talk BLA obviously but people we

Tony Polak

that Right. why the so shown so knowing not process? I seems much that product know to Do the is statistically works, she when already up have you held mean,

Ted Harris

quality really doing it together, will all now work the I right BLA. think go the putting is work, shelf around into BLA work, that manufacturing life largely stability the

think that's opposed I at our the really timeframe understanding be the as else. at will of limiting work to situation. really So work anything hand here the and least the That's work that

Operator

would of section. and like Ted to turn Harris, question the we end back gentleman, closing and have to call the answer reached for Ladies I the remarks. CEO,

Ted Harris

I'd and we just weeks thank of everybody your and in with you forums, the various to call like continued will I'm we coming forward out November. for for today. interest our thank to reporting you but QX talking support the many sure joining be look progress at in

lot now. for thanks goodbye So a and

Operator

conference. today's concludes This

for You may disconnect day. your at Thank lines time participation wonderful this and you have a your

Balchem (BCPC) 4 Aug 192019 Q2 Earnings call transcript